Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Cinqair Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Cinqair (reslizumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B coverage of Cinqair (reslizumab) for Medicare Advantage members with severe eosinophilic asthma requiring add-on therapy. It specifies covered use, clinical documentation, eosinophil thresholds, prescriber qualifications, exclusions, billing, and authorization duration.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyCinqair (reslizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting prior therapies and responses, current patient weight, and qualifying eosinophil results.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Eosinophilic asthmaCovered indication
    ≥150 cells/mcLEosinophil threshold at therapy start
    ≥300 cells/mcLAlternative eosinophil threshold
    2 yearsInitial coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 years
    Reauthorization
    J2786HCPCS billing code

    Coverage Criteria

    Initial Coverage Criteria

    Covered when all initial medical-necessity requirements are met:

    Initial coverage requirements

    • Clinical and documentation requirements

      • Cinqair is requested for severe eosinophilic asthma as add-on therapy.
      • Medical records supporting the request, including documentation of prior therapies and responses to treatment, are provided.
      • The patient's current weight is provided.
      • The prescriber is a specialist or has consulted with a specialist for the condition being treated.
      • ONE of the following eosinophil thresholds

        • The eosinophil level is greater than or equal to 150 cells/mcL at therapy start.≥150 cells/mcL at therapy start
        • The eosinophil level is greater than or equal to 300 cells/mcL in the previous 12 months.≥300 cells/mcL in the previous 12 months

    Reauthorization Criteria

    Reauthorization is available when the following requirements are met:

    Reauthorization requirements

    • Coverage may be reauthorized for two years.2 years
    • The dose follows FDA-approved labeling or accepted standards of medical practice.

    Cinqair must not be used in combination with other biologic drugs.

    Coding and Clinical Thresholds

    HCPCSHCPCSCovered
    J2786Cinqair (reslizumab)
    Eosinophil Level at Therapy Start
    Eosinophil thresholdGreater than or equal to 150 cells/mcL
    TimingAt therapy start
    Coverage contextRequired for initial coverage of severe eosinophilic asthma
    Eosinophil Level in Previous 12 Months
    Eosinophil thresholdGreater than or equal to 300 cells/mcL
    TimingDuring the previous 12 months
    Coverage contextAlternative threshold for initial coverage of severe eosinophilic asthma

    Provider Submission Requirements

    Prior Authorization

    Specialist Prescriber or Consultation Required

    Prior authorization must be submitted by a specialist prescriber or by a prescriber who has consulted with a specialist for the condition being treated.

    Prior Authorization

    Two-Year Authorization and Appropriate Dosing

    Initial coverage and reauthorization are each approved for two years. The dose must follow FDA-approved labeling or accepted standards of medical practice.

    Documentation Required

    Submit Medical Records and Treatment History

    Submit medical records supporting the request, including documentation of prior therapies and the patient's responses to treatment.

    Clinical Background

    Cinqair (reslizumab) is an interleukin-5 (IL-5) antagonist indicated as add-on therapy for severe eosinophilic asthma. IL-5 supports the growth and survival of eosinophils, which contribute to inflammation in the lungs.

    Initial Therapy Criteria

    Initial Severe Eosinophilic Asthma Therapy

    Initial coverage is available when all documentation and clinical requirements are met:

    Initial Cinqair therapy

    • Required clinical documentation

      • The request is for severe eosinophilic asthma add-on therapy.
      • Medical records supporting the request, including documentation of prior therapies and responses to treatment, are provided.
      • The patient's current weight is provided.
      • The prescriber is a specialist or has consulted with a specialist for the condition being treated.

    Continuation and Reauthorization

    Continuation Criteria

    Reauthorization is available for two years:

    Continuation authorization

    • Cinqair may be reauthorized for two years.2 years
    • Dosing follows FDA-approved labeling or accepted standards of medical practice.

    Quantity and Billing Unit

    Cinqair (Reslizumab)
    DrugCinqair (reslizumab)
    Billing unit1 mg
    HCPCS codeJ2786
    Policy Summary
    PayerGold Coast Health Plan
    PolicyCinqair (reslizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting prior therapies and responses, current patient weight, and qualifying eosinophil results.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Submission RequirementsClinical BackgroundInitial Therapy CriteriaContinuation and ReauthorizationQuantity and Billing Unit
    Documentation Required

    Current Patient Weight Required

    Provide the patient's current weight with the authorization request.

    Documentation Required

    Eosinophil Laboratory Documentation

    For initial coverage of severe eosinophilic asthma, submit laboratory results documenting an elevated eosinophil level meeting the applicable threshold.

    • At therapy start: ≥ 150 cells/mcL
    • Or during the previous 12 months: ≥ 300 cells/mcL
    Denial Risk

    Concurrent Biologic Therapy Excluded

    Cinqair must not be used in combination with another biologic drug. Requests for concurrent use with another biologic are excluded from coverage.

    Denial Risk

    Eosinophil Threshold Not Met

    Initial coverage is not supported when the required eosinophil threshold is not met at therapy start or during the prior 12 months.

    • Therapy-start eosinophil level must be ≥ 150 cells/mcL, or
    • Eosinophil level during the previous 12 months must be ≥ 300 cells/mcL

    ONE of the following eosinophil thresholds

    • The patient has an elevated eosinophil level greater than or equal to 150 cells/mcL at therapy start.≥150 cells/mcL at therapy start
    • The patient has an elevated eosinophil level greater than or equal to 300 cells/mcL in the previous 12 months.≥300 cells/mcL in the previous 12 months